Diversified Healthcare Trust (NASDAQ:DHC) Releases Earnings Results, Misses Expectations By $0.04 EPS

Diversified Healthcare Trust (NASDAQ:DHC) announced its earnings results on Monday. The real estate investment trust reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04), Zacks reports. Diversified Healthcare Trust had a negative net margin of 18.83% and a negative return on equity of 14.69%.

Diversified Healthcare Trust Stock Up 3.8%

Shares of NASDAQ:DHC traded up $0.16 on Monday, hitting $4.42. 1,080,925 shares of the company’s stock were exchanged, compared to its average volume of 889,166. Diversified Healthcare Trust has a 1-year low of $2.00 and a 1-year high of $4.65. The company has a market capitalization of $1.07 billion, a PE ratio of -3.71 and a beta of 2.65. The company has a debt-to-equity ratio of 1.42, a quick ratio of 6.35 and a current ratio of 6.35. The firm’s 50-day moving average is $4.20 and its 200 day moving average is $3.59.

Diversified Healthcare Trust Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 13th. Shareholders of record on Monday, October 27th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Monday, October 27th. Diversified Healthcare Trust’s payout ratio is -3.36%.

Institutional Trading of Diversified Healthcare Trust

Several institutional investors have recently modified their holdings of DHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Diversified Healthcare Trust by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 130,756 shares of the real estate investment trust’s stock worth $314,000 after acquiring an additional 5,544 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Diversified Healthcare Trust by 158.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,862,334 shares of the real estate investment trust’s stock worth $9,270,000 after purchasing an additional 2,370,459 shares during the last quarter. Strs Ohio acquired a new stake in shares of Diversified Healthcare Trust during the first quarter worth about $103,000. JPMorgan Chase & Co. lifted its holdings in shares of Diversified Healthcare Trust by 10.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 923,963 shares of the real estate investment trust’s stock valued at $3,308,000 after purchasing an additional 84,572 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Diversified Healthcare Trust by 1.9% in the 2nd quarter. Rhumbline Advisers now owns 388,581 shares of the real estate investment trust’s stock valued at $1,391,000 after purchasing an additional 7,084 shares during the period. Hedge funds and other institutional investors own 75.98% of the company’s stock.

Analyst Upgrades and Downgrades

DHC has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Diversified Healthcare Trust in a report on Wednesday, October 8th. B. Riley upped their price objective on Diversified Healthcare Trust from $4.50 to $5.50 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Diversified Healthcare Trust presently has an average rating of “Hold” and a consensus target price of $5.50.

About Diversified Healthcare Trust

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants.